By Stacey Stevens, President & CEO, SimBioSys Every October, pink ribbons remind us of how far we’ve come in the fight against breast cancer — and how far we still have to go. Despite remarkable progress in awareness, screening, and…

The ESMO Breast Cancer 2022 took place in Berlin on May 3 – 5. A well-attended conference covering a broad range of breast cancer topics. Our team was there to present three posters. Here are our takeaway messages from the…

The last decade in cancer care has been defined by the rapid emergence (and in some cases, dominance), of monoclonal antibody therapies, where they serve as a critical foundation of oncologic care.

Our chief medical officer, Dr. Anuja Antony, represented SimBioSys at the ESMO 2022 conference last month. Among the many exciting advances and developments in the breast cancer field, two topics took center stage: 1) antibody-drug conjugates (ADCs) and 2) human…

SimBioSys® is developing the TumorScope® platform to capture what is truly unique about each patient. The NVIDIA GPU-powered platform takes a holistic and multiscale approach to assess tumor response to therapy. Pulling together all the information that’s painstakingly acquired during…

Our team was present at the American Society of Clinical Oncology (ASCO) annual meeting that took place from June 3 – 7, 2022. Perhaps the most impactful moment for breast cancer oncologists and researchers at the conference took place during…

The ESMO Breast Cancer 2022 took place in Berlin on May 3 – 5. A well-attended conference covering a broad range of breast cancer topics. Our team was there to present three posters. Here are our takeaway messages from the…

After two consecutive years of virtually holding the annual meeting of the American Association for Cancer Research (AACR), the conference returned to an in-person format, while retaining a hybrid option for those who prefer to join virtually.

From December 7th -10th the San Antonio Breast Cancer Symposium gathered breast cancer experts from all over the world to share the latest medical and scientific advances in the breast cancer field. Our team attended the meeting to present our…

Precision medicine has come a long way in terms of breast cancer treatment but more needs to be done for the non-responder patients, for those who need financial support, for minorities. Precision cancer care needs to be available for all.